TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3802705

Group type: EXPERIMENTAL
Intervention: Nitrendipine (mean dose 32 mg/day)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Acebutolol (414 mg/day)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Mefruside added to nitrendipine or acebutolol
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Nitrendipine and Acebutolol (both treatments)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Nitrendipine
Number of subjects: 60
Study: 27895238

Group type: EXPERIMENTAL
Intervention: Immediate-release methylphenidate
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Reading program (phonologically or strategy‐based reading instruction, or general academic strategy and social skills training)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 25201932

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) training for PCPs
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) training for PCPs (3 trainings)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Patients seen by MI‐trained PCPs
Number of subjects: 171

Group type: COMPARATOR
Intervention: Control group (untrained PCPs)
Number of subjects: 171
Study: 22229612

Group type: EXPERIMENTAL
Intervention: Proximal femoral nail antirotation (PFNA)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Reconstruction nail (Recon)
Number of subjects: 23
Study: 20413522

Group type: EXPERIMENTAL
Intervention: Infliximab (5 mg/kg) intravenously at weeks 0, 2, 6, and 14
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 11
Study: 18403886

Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine (CHX)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: BioPure MTAD
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: 2.6% sodium hypochlorite (NaOCl)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Infected dentin tubes (positive control)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Sterile dentin tubes (negative control)
Number of subjects: 110
Study: 16217977

Group type: EXPERIMENTAL
Intervention: 5-day telithromycin (800 mg once daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 10-day amoxicillin-clavulanate (500/125 mg 3 times daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 10-day cefuroxime axetil (250 mg twice daily)
Number of subjects: 0
Study: 12016483

Group type: EXPERIMENTAL
Intervention: Gamma probe
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: iPTH
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Neither technique
Number of subjects: 150
Study: 10228912

Group type: EXPERIMENTAL
Intervention: Dynamic Health Assessment (DynHA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SF‐36 and SF‐12 instruments
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patient-based outcomes measure
Number of subjects: 0
Study: 7757354

Group type: EXPERIMENTAL
Intervention: Increased activities of glutamic‐pyruvic transaminase (GPT) and catalase
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lower levels of GPT in women
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher catalase activity in women
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blood serum catalase measurements
Number of subjects: 0
Study: 1693714

Group type: EXPERIMENTAL
Intervention: Felodipine (2.5, 5, and 10 mg b.i.d. for 2 weeks each)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 293045

Group type: EXPERIMENTAL
Intervention: Prophylactic systemic antibiotics
Number of subjects: 142

Group type: COMPARATOR
Intervention: Control (no antibiotics)
Number of subjects: 142
Study: 30681939

Group type: EXPERIMENTAL
Intervention: Reduced fat (RF)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: n-3-enriched reduced fat (n-3RF)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Normal fat (NF)
Number of subjects: 18
Study: 27951450

Group type: EXPERIMENTAL
Intervention: Dose-dense chemotherapy
Number of subjects: 1549

Group type: COMPARATOR
Intervention: Standard-interval chemotherapy
Number of subjects: 1549
Study: 26154930

Group type: EXPERIMENTAL
Intervention: CD34+ cell infusion (1.0 x 10^7 cells/vessel)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: CD34+ cell infusion (3.0 x 10^7 cells/vessel)
Number of subjects: 38
Study: 23229239

Group type: EXPERIMENTAL
Intervention: CO₂ laser technique
Number of subjects: 48

Group type: COMPARATOR
Intervention: Conventional surgery using cold knife
Number of subjects: 48
Study: 22166738

Group type: EXPERIMENTAL
Intervention: Stoppa method
Number of subjects: 117

Group type: COMPARATOR
Intervention: TEP method
Number of subjects: 117
Study: 20090145

Group type: EXPERIMENTAL
Intervention: Odontic Microsystem treatment developed by R. Voll and R. Dale
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Complex treatment for patients with inner organ pathology
Number of subjects: 100
Study: 16446328

Group type: EXPERIMENTAL
Intervention: Oral irinotecan (40 mg/m2/d MTD without cefixime; 60 mg/m2/d MTD with cefixime)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cefixime (8 mg/kg/d beginning 5 days before irinotecan and continuing throughout the course)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cefixime with oral irinotecan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral irinotecan without cefixime
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral irinotecan with cefixime
Number of subjects: 0
Study: 15224273

Group type: EXPERIMENTAL
Intervention: Sertraline treatment
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 93
Study: 11423921

Group type: COMPARATOR
Intervention: High-Fat Diet (HFD)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Mediterranean Diet (MD)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Red Wine Supplementation (240 ml/day)
Number of subjects: 21
Study: 9243749

Group type: EXPERIMENTAL
Intervention: Hep B-3 vaccine containing both preS1- and preS2-derived proteins in addition to hepatitis B surface antigen
Number of subjects: 86

Group type: COMPARATOR
Intervention: Hepatitis B surface antigen vaccine
Number of subjects: 86
Study: 7961239

Group type: EXPERIMENTAL
Intervention: Intra-arterial injection of naloxone HCl (60 micrograms)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Intra-arterial vehicle (saline)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Systemic infusion of naloxone (4 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Systemic vehicle
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (no naloxone or vehicle)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Intra-arterial naloxone
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Systemic naloxone
Number of subjects: 8

Group type: COMPARATOR
Intervention: Vehicle (saline)
Number of subjects: 8
Study: 3591419

Group type: EXPERIMENTAL
Intervention: Bilateral ECT
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Right unilateral ECT
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Low dosage, titrated ECT
Number of subjects: 34
Study: 30158219

Group type: EXPERIMENTAL
Intervention: Patients with alcohol dependence
Number of subjects: 236

Group type: COMPARATOR
Intervention: Individuals without alcohol dependence
Number of subjects: 236
Study: 27544007

Group type: EXPERIMENTAL
Intervention: 24-month dual-antiplatelet therapy (DAPT)
Number of subjects: 459

Group type: COMPARATOR
Intervention: 6-month dual-antiplatelet therapy (DAPT)
Number of subjects: 459

Group type: EXPERIMENTAL
Intervention: Clinically relevant bleeding (including Bleeding Academic Research Consortium type 3 or 5, TIMI, and GUSTO scales)
Number of subjects: 459

Group type: EXPERIMENTAL
Intervention: Secondary ischemic endpoints (overall or cardiovascular mortality, myocardial infarction, stent thrombosis)
Number of subjects: 459
Study: 24352823

Group type: EXPERIMENTAL
Intervention: I-ONE therapy administered postoperatively four hours per day for 60 days
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: I-ONE therapy
Number of subjects: 33
Study: 23498849

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (200,000 IU retinyl acetate every 6 months)
Number of subjects: 1000000

Group type: COMPARATOR
Intervention: Control (no vitamin A supplementation)
Number of subjects: 1000000

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 1000000
Study: 20444849

Group type: EXPERIMENTAL
Intervention: Trastuzumab in combination with capecitabine
Number of subjects: 0
Study: 19040592

Group type: EXPERIMENTAL
Intervention: Benazepril plus hydrochlorothiazide
Number of subjects: 11464

Group type: COMPARATOR
Intervention: Benazepril plus amlodipine
Number of subjects: 11464
Study: 16625329

Group type: EXPERIMENTAL
Intervention: Surgery alone (Treatment Arm A)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgery, then 1-hexylcarbamoyl-5-fluorouracil (Treatment Arm B)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgery + 1-hexylcarbamoyl-5-fluorouracil + mitomycin C (Treatment Arm D)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgery, then 1-hexylcarbamoyl-5-fluorouracil (Treatment Arm C)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Group W (well-differentiated adenocarcinoma)
Number of subjects: 0
Study: 12794547

Group type: EXPERIMENTAL
Intervention: Two-dose intrapartum neonatal nevirapine regimen
Number of subjects: 109
Study: 10845685

Group type: EXPERIMENTAL
Intervention: Self-emulsifying vitamin E preparation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Natopherol (commercial product)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Self-emulsifying vitamin E preparation and Natopherol
Number of subjects: 0
Study: 8843210

Group type: EXPERIMENTAL
Intervention: Canarypox expressing HIV-1MN gp 160 followed by recombinant envelope protein boosts
Number of subjects: 20
Study: 1640362

Group type: EXPERIMENTAL
Intervention: Experimental formulation of theophylline with 70% drum-dried corn starch (DDCS-70)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Theo-dur (reference sustained-release formulation)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Experimental formulation with 50% starch
Number of subjects: 2
Study: 6132612

Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Trimeprazine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 30660722

Group type: EXPERIMENTAL
Intervention: Quadriceps strengthening intervention (10 sessions over 28 days)
Number of subjects: 53
Study: 30409212

Group type: EXPERIMENTAL
Intervention: IIb preserving superselective neck dissection
Number of subjects: 32

Group type: COMPARATOR
Intervention: Conventional supraomohyoid neck dissection
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Quality of life measured by FACT-HN version 4 questionnaire
Number of subjects: 32
Study: 27782892

Group type: EXPERIMENTAL
Intervention: Probiotic treatment (5×10^9 CFU B. lactis B94)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Synbiotic treatment (5×10^9 CFU B. lactis B94 and 900 mg inulin)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Prebiotic treatment (900 mg inulin)
Number of subjects: 71
Study: 25251432

Group type: EXPERIMENTAL
Intervention: Low-dose continuous (3 mg/kg q 24 hr)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: High-dose intermittent (three doses of 45 mg/kg q 6 hr repeated q 1 wk)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Both low-dose continuous and high-dose intermittent
Number of subjects: 24
Study: 22133661

Group type: EXPERIMENTAL
Intervention: Vaginal ring (daily dose of 15 mcg ethinylestradiol/120 mcg etonogestrel)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Short or long CAG repeats
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Mood of the woman
Number of subjects: 55
Study: 20663495

Group type: EXPERIMENTAL
Intervention: Oral contraception (OC) for 6 to 8 weeks before assisted reproduction treatment (ART)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No pre-treatment with oral contraception (OC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral contraception (OC) for 6 to 8 weeks before ART
Number of subjects: 0
Study: 17167265

Group type: EXPERIMENTAL
Intervention: TiF(4)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 2-hour pellicle
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 2-hour pellicle + TiF(4)
Number of subjects: 32
Study: 14713317

Group type: EXPERIMENTAL
Intervention: Interviewer-administered CRQ
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Self-administered CRQ
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Standardised dyspnoea questions
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Individualised dyspnoea questions
Number of subjects: 162

Group type: COMPARATOR
Intervention: Control group (stable COPD patients without intervention)
Number of subjects: 162
Study: 11673291

Group type: EXPERIMENTAL
Intervention: Hydrogel IOL
Number of subjects: 100

Group type: COMPARATOR
Intervention: Acrylic IOL
Number of subjects: 100
Study: 9678814

Group type: EXPERIMENTAL
Intervention: 1 week co-therapy with amoxycillin (1 g b.d.) and clarithromycin (500 mg b.d.)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: 2 week co-therapy with amoxycillin (1 g b.d.) and clarithromycin (500 mg b.d.)
Number of subjects: 67
Study: 7735085

Group type: EXPERIMENTAL
Intervention: Assertive case management
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 2591463

Group type: EXPERIMENTAL
Intervention: Alfuzosin 5 mg
Number of subjects: 6

Group type: COMPARATOR
Intervention: Prazosin 1 mg
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Alfuzosin 10 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Alfuzosin 1 mg and 5 mg
Number of subjects: 6
Study: 29564482

Group type: COMPARATOR
Intervention: LY2140023 (10, 40, and 160 mg)
Number of subjects: 32

Group type: COMPARATOR
Intervention: LY2979165 (20 and 60 mg)
Number of subjects: 32
Study: 27392846

Group type: EXPERIMENTAL
Intervention: Intensive Rehabilitation Program (IRP) starting on the second postoperative day
Number of subjects: 126

Group type: COMPARATOR
Intervention: Standard Rehabilitation Program (SRP) starting after 3 weeks
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Both IRP and SRP
Number of subjects: 126
Study: 26063068

Group type: EXPERIMENTAL
Intervention: Iron (300 mg ferrous sulfate) + 0.40 mg folate
Number of subjects: 2371

Group type: COMPARATOR
Intervention: Placebo + 0.40 mg folate
Number of subjects: 2371
Study: 23810047

Group type: EXPERIMENTAL
Intervention: Probiotic curd
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Probiotic toothpaste
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study: 21903021

Group type: EXPERIMENTAL
Intervention: Raloxifene (60 mg/d)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 18362867

Group type: EXPERIMENTAL
Intervention: Guanfacine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16539557

Group type: EXPERIMENTAL
Intervention: Direct bonding with Transbond XT
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Indirect bonding with Transbond XT/Sondhi Rapid Set (chemically cured)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Indirect bonding with Enlight LV/Orthosolo (light cured)
Number of subjects: 60
Study: 12754885

Group type: EXPERIMENTAL
Intervention: Angiotensin receptor blockers (ARBs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ACE inhibitors or ARBs
Number of subjects: 0
Study: 10933346

Group type: EXPERIMENTAL
Intervention: abciximab
Number of subjects: 0
Study: 8815481

Group type: EXPERIMENTAL
Intervention: Amikacin once daily (group A)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Amikacin thrice daily plus carbenicillin (group B)
Number of subjects: 50
Study: 1444488

Group type: EXPERIMENTAL
Intervention: UFT administration
Number of subjects: 182

Group type: COMPARATOR
Intervention: FT‐E administration
Number of subjects: 182
Study: 2861767

Group type: EXPERIMENTAL
Intervention: Terfenadine 60 mg bid
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: Chlorpheniramine 4 mg tid
Number of subjects: 397

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: Terfenadine
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: Chlorpheniramine
Number of subjects: 397
Study: 31084483

Group type: EXPERIMENTAL
Intervention: Parent Forum
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Parent Forum II
Number of subjects: 41

Group type: COMPARATOR
Intervention: Monthly phone calls from a mental health professional
Number of subjects: 41

Group type: COMPARATOR
Intervention: Services as usual
Number of subjects: 41
Study: 30030699

Group type: EXPERIMENTAL
Intervention: Hazelnut and cocoa spread (60 g)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Milk chocolate (60 g)
Number of subjects: 20
Study: 26891618

Group type: EXPERIMENTAL
Intervention: RXU (RelyX Unicem)
Number of subjects: 34

Group type: COMPARATOR
Intervention: RXU+E (RelyX Unicem with selective enamel etching)
Number of subjects: 34
Study: 24684948

Group type: EXPERIMENTAL
Intervention: Physical activity program for patients with dementia and their caregivers for 3 months, designed by Primary Health Care professionals.
Number of subjects: 134

Group type: COMPARATOR
Intervention: Regular care (Control group).
Number of subjects: 134
Study: 21523325

Group type: EXPERIMENTAL
Intervention: Unidirectional barbed Glycolic acid‐trimethylene carbonate (group 2)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Monofilament Polyglecaprone‐25 (group 1)
Number of subjects: 55
Study: 21239366

Group type: EXPERIMENTAL
Intervention: Computer-delivered ORLA
Number of subjects: 25

Group type: COMPARATOR
Intervention: SLP-delivered ORLA
Number of subjects: 25
Study: 18204476

Group type: EXPERIMENTAL
Intervention: St John's wort
Number of subjects: 21

Group type: COMPARATOR
Intervention: gliclazide alone
Number of subjects: 21
Study: 16055956

Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/d
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Alendronate 10 mg/d
Number of subjects: 165
Study: 11876700

Group type: EXPERIMENTAL
Intervention: Omeprazole, 20 mg in the morning
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Famotidine, 10 mg at bedtime
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Famotidine, 10 mg at 05.30 h
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Famotidine, 10 mg at bedtime and at 05.30 h
Number of subjects: 12
Study: 10469339

Group type: EXPERIMENTAL
Intervention: Nitric oxide releasing cream (mixed with nitrite and ascorbic acid, applied three times daily)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nitric oxide releasing cream (high dose)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nitric oxide releasing cream (48 h exposure)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Ascorbic acid alone (control)
Number of subjects: 12
Study: 7562391

Group type: EXPERIMENTAL
Intervention: African American youth
Number of subjects: 0

Group type: COMPARATOR
Intervention: White American youth
Number of subjects: 0
Study: 2186579

Group type: EXPERIMENTAL
Intervention: Captopril (Cp)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Nifedipine (N) or Isosorbide dinitrate (S)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Digoxin (Dx) and Furosemide (F)
Number of subjects: 50
Study: 37747

Group type: EXPERIMENTAL
Intervention: Dihydrotachysterol (DHT) given orally
Number of subjects: 8

Group type: COMPARATOR
Intervention: Synthetic salmon calcitonin (SCT)
Number of subjects: 8
Study: 30477032

Group type: EXPERIMENTAL
Intervention: Suture closure
Number of subjects: 350

Group type: COMPARATOR
Intervention: Staple closure
Number of subjects: 350
Study: 28454583

Group type: EXPERIMENTAL
Intervention: PRO feedback
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PRO feedback and Living with lymphoma intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study: 26149165

Group type: EXPERIMENTAL
Intervention: Interactive video intervention based on behavioral decision research
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Revised interactive video intervention
Number of subjects: 0
Study: 23816662

Group type: EXPERIMENTAL
Intervention: Phonological self-cued retrieval strategy
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Semantic self-cued retrieval strategy
Number of subjects: 19
Study: 21551506

Group type: EXPERIMENTAL
Intervention: Licofelone
Number of subjects: 161

Group type: COMPARATOR
Intervention: Naproxen
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Baseline score of bone marrow lesions (BML) in the medial compartment
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Medial joint space width (JSW) as assessed by standardised radiographs
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Presence of severe medial meniscal tear
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Medial meniscal extrusion
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: C-reactive protein level
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Change in cartilage volume of the medial compartment
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Change in cartilage volume of the global knee
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Reduction in the JSW of greater than 7%
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: WOMAC pain scores
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: WOMAC function scores
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Baseline severe medial meniscal tear
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Presence of medial BML
Number of subjects: 161
Study: 18808275

Group type: EXPERIMENTAL
Intervention: Credit card presence
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Decomposition strategy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Scrip (stored value certificate)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cash and gift certificates
Number of subjects: 0
Study: 17164314

Group type: EXPERIMENTAL
Intervention: PTH(1-84) therapy alone
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: PTH(1-84) therapy with alendronate
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: PTH(1-84) therapy
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Defined algorithm for managing hypercalcemia
Number of subjects: 178